cellular
immunity using HPV16/18 L1 VLP vaccine formulated with the
MPL/aluminium salt combination (AS04)compared to aluminium salt only.
Vaccine 2006
6. Viscidi R, Schiffman M, Hildesheim A, et al. Seroreactivity to Human
Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV
Infection: Results from a Population-Based Study in Costa Rica. Cancer
Epidemiology, Biomarkers & Prevention, 2004;13, 324-327
7. Australian Label
8. World Health Organization. Initiative for Vaccine Research.
http://www.who.int/vaccine_research/diseases/hpv/en/ Accessed on May
2, 2007
9. Jemal A, Murray T, Ward E, Sammuels A et al. Cancer Statistics, 2005.
Cancer Journal for Clinicians 2005; 55; 10-30.
10. Basen-Engquist K, Paskett ED, et al. Cervical cancer. Cancer 2003; 98:
2009-2014.
11. Dunne E, Unger E, et al. Prevalence of HPV Infection Among Females in
the United States. Journal of the American Medical Association, 2007;
297: 813-819
CONTACT: U.S. Media Inquiries: Liad Diamond, +1-919-483-2839,
NancyPekarek, +1-215-751-7709, or Alice Hunt, +1-215-751-7709; U.K.
MediaInquiries: Philip Thomson, +44-20-8047-5502, Gwenan
White,+44-20-8047-5502, or Joss Mathieson, +44-20-8047-5502;
U.S.Analyst/Investor Inquiries: Frank Murdolo, +1-215-751-7002, or
Tom Curry,+1-215-751-5419; European Analyst/Investor Inquiries:
Anita Kidgell,+44-20-8047-5542, Sally Ferguson, +44-20-8047-5543,
or David Mawdsley,+44-20-8047-5564; GSK Biologicals: Stella Gu,
+32-2-656-3533, or ChrisHunter-Ward, +32-2-656-3075
Web site: http://www.gsk.com/http://www.gsk.com/media/
Company News On-Call: http://www.prnewswi
'"/>
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Largest National U.S. Healthcare Facility MRSA Study Reveals
Infection Rates Eight Times Greater Than Previous Estimates2.
Vaccine Can Prevent Cervical Cancer and Precancerous Lesions3.
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
Age4.
New England Journal of Medicine Publishes New Data on Gardasil,
Mercks Cervical Cancer Vaccine5.
Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100
Percent Protection Against Precancerous Lesions Caused By
Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than
Five Years6.
Nventa Announces Presentation of Positive HspE7 Data from
NCI-Sponsored Clinical Trial in Cervical Dysplasia7.
Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy8.
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer9.
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs10.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial11.
Protox Announces Positive Clinical Data from Prostate Cancer Study